Abstract:Ethnopharmacological relevance Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed that MDCH improves glycemic and lipid metabolism, enhances pancreatic function, and alleviates insulin resistance in patients with T2D and diabetic rats. Evidence has demonstrated that MDCH protects pancreatic β cells via regulating the gene expression of sirtuin 1 (SIRT1) and forkhead box protein O1 (FOXO1). However, the detailed mechanism remains unclear. Aim of the study Dedifferentiation of pancreatic β cells mediated by FOXO1 has been recognized as the main pathogenesis of T2D. This study aims to investigate the therapeutic effects of MDCH on T2D in vitro and in vivo to elucidate the potential molecular mechanisms. Materials and methods To predict the key targets of MDCH in treating T2D, network pharmacology methods were used. A T2D model was induced in diet-induced obese (DIO) C57BL/6 mice with a single intraperitoneal injection of streptozotocin. Glucose metabolism indicators (oral glucose tolerance test, insulin tolerance test), lipid metabolism indicators (total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol), inflammatory factors (C-reactive protein, interleukin 6, tumor necrosis factor alpha), oxidative stress indicators (total antioxidant capacity, superoxide dismutase, malondialdehyde), and hematoxylin and eosin staining were analyzed to evaluate the therapeutic effect of MDCH on T2D. Immunofluorescence staining and quantification of FOXO1, pancreatic and duodenal homeobox 1 (PDX1), NK6 homeobox 1 (NKX6.1), octamer-binding protein 4 (OCT4), neurogenin 3 (Ngn3), insulin, and SIRT1, and Western blot analysis of insulin, SIRT1, and FOXO1 were performed to investigate the mechanism by which MDCH inhibited pancreatic β-cell dedifferentiation. Results The chemical ingredients identified in MDCH were predicted to be important for signaling pathways related to lipid metabolism and insulin resistance, including lipids in atherosclerosis, the advanced glycation end product receptor of the advanced glycation end product signaling pathway, and the FOXO signaling pathway. Experimental studies showed that MDCH improved glucose and lipid metabolism in T2D mice, alleviated inflammation and oxidative stress damage, and reduced pancreatic pathological damage. Furthermore, MDCH upregulated the expression levels of SIRT1, FOXO1, PDX1, and NKX6.1, while downregulating the expression levels of OCT4 and Ngn3, which indicated that MDCH inhibited pancreatic dedifferentiation of β cells. Conclusions MDCH has therapeutic effects on T2D, through regulating the SIRT1/FOXO1 signalling pathway to inhibit pancreatic β-cell dedifferentiation, which has not been reported previously.

Β-Cell Dedifferentiation in Patients with T2D with Adequate Glucose Control and Nondiabetic Chronic Pancreatitis.

Paraneoplastic Β Cell Dedifferentiation in Non-Diabetic Patients with Pancreatic Cancer.

Modeling human pancreatic beta cell dedifferentiation

β-Cell Dedifferentiation in HOMA-βlow and HOMA-βhigh Subjects

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?

Β-Cell Dynamics in Type 2 Diabetes and in Dietary and Exercise Interventions

Loss of β-cell identity and dedifferentiation, not an irreversible process?

The Role of Inflammation in β-cell Dedifferentiation

Molecular Mechanism of Islet Β-Cell Functional Alternations During Type 2 Diabetes.

Beta-cell function and glucose metabolism in patients with chronic pancreatitis

Systematic Single-Cell Analysis Provides New Insights into Heterogeneity and Plasticity of the Pancreas.

Β Cell Dedifferentiation: New Insight into the Pathogenesis of Β Cell Failure in Type 2 Diabetes——gone Backward Already...and Coming Back Again?

Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes

187-OR: Declines in ß-Cell Glucose Responsiveness Correlate with Loss of Glucose Metabolism during T1D Pathogenesis

Downregulation of Sirt3 contributes to β-cell dedifferentiation via FoxO1 in type 2 diabetic mellitus

Reversibility Ofβ-Cell-specific Transcript Factors Expression by Long-Term Caloric Restriction in Db/db Mouse

Enhanced T Cell Glucose Uptake Is Associated With Progression of Beta-Cell Function in Type 1 Diabetes

A Brief Review of the Mechanisms of β-Cell Dedifferentiation in Type 2 Diabetes

Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification

Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling